Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites

Marsousi, Niloufar; Daali, Youssef; Fontana, Pierre; Reny, Jean-Luc; Ancrenaz-Sirot, Virginie; Calmy, Alexandra; Rudaz, Serge; Desmeules, Jules Alexandre; Samer, Caroline Flora

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites
Authors		Marsousi, Niloufar Daali, Youssef Fontana, Pierre Reny, Jean-Luc Ancrenaz-Sirot, Virginie Calmy, Alexandra Rudaz, Serge Desmeules, Jules Alexandre Samer, Caroline Flora show all authors [1 - 9]
Published in		Clinical Pharmacokinetics. 2018, vol. 57, no. 10, p. 1347-1354
Abstract		Prasugrel and clopidogrel are inhibitors of the ADP-P2Y12 platelet receptor used in acute coronary syndrome patients. They require bioactivation via isoenzymes such as cytochrome P450 (CYP) 3A4, CYP2C19 and CYP2B6. Ritonavir and cobicistat are potent CYP3A inhibitors, prescribed as pharmacokinetic (PK) enhancers in the treatment of human immunodeficiency virus (HIV) infection.
Identifiers		DOI: 10.1007/s40262-018-0637-6 PMID: 29453687
Full text		Article (Published version) (723 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie et soins intensifs Faculté des sciences / Section des sciences pharmaceutiques
Research group		Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Citation (ISO format)		MARSOUSI, Niloufar et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. In: Clinical Pharmacokinetics, 2018, vol. 57, n° 10, p. 1347-1354. https://archive-ouverte.unige.ch/unige:111012